A carregar...
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Checkpoint inhibitor-based immunotherapies that target cytotoxic T lymphocyte antigen 4 (CTLA4) or the programmed cell death 1 (PD1) pathway have achieved impressive success in the treatment of different cancer types. Yet, only a subset of patients derive clinical benefit. It is thus critical to und...
Na minha lista:
| Publicado no: | Nat Rev Cancer |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6705396/ https://ncbi.nlm.nih.gov/pubmed/30755690 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41568-019-0116-x |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|